Bristol-Myers Squibb supporting efforts to help survivors

Bristol-Myers SquibbBristol-Myers Squibb is joining the world community in providing immediate help for survivors of the massive earthquake that struck Haiti on January 12. The company has already shipped a large donation of antibiotics through Project Hope, an organization providing direct relief to disaster victims. In addition, Bristol-Myers Squibb France is sending medicine to help the injured through Tulipe, an organization that facilitates pharmaceutical company donations to provide an emergency response to people in distress as a result of acute health crises, natural disasters or conflicts.

In addition to the medicines the company has shipped or is sending to help the injured, the Bristol-Myers Squibb Foundation will donate a total of $200,000 to three organizations providing disaster relief. The organizations are:

  • The Catholic Medical Mission Board, which has been working in Haiti since 1912 to provide medicines and much needed supplies and support;
  • The American Red Cross, which is giving $10 million to support a number of relief efforts in the country, many already under way; and
  • Partners in Health, which has been working in Haiti since 1987 to address health care needs.

The Bristol-Myers Squibb Foundation will match two-for-one contributions made by employees in the U.S. and Puerto Rico to the following organizations assisting disaster relief efforts in Haiti:

  • AmeriCares
  • American Red Cross
  • CARE
  • Catholic Medical Mission Board
  • Direct Relief International
  • Doctors Without Borders
  • Partners in Health
  • Project Hope
  • Save the Children

Bristol-Myers Squibb will continue to monitor the situation with its relief partners.

About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company committed to discovering, developing and delivering innovative medicines that help patients prevail over serious diseases. For more information, please visit www.bms.com.

Most Popular Now

Scientists uncover SARS-CoV-2-specific T cell immu…

The study by scientists from Duke-NUS Medical School, in close collaboration with the National University of Singapore (NUS) Yong Loo Lin School of Medicine, Singapore Ge...

Common FDA-approved drug may effectively neutraliz…

A common drug, already approved by the Food and Drug Administration (FDA), may also be a powerful tool in fighting COVID-19, according to research published this week in ...

Drug linked to 45% lower risk of dying among COVID…

Critically ill COVID-19 patients who received a single dose of a drug that calms an overreacting immune system were 45% less likely to die overall, and more likely to be ...

Neutralizing antibodies isolated from COVID-19 pat…

Researchers at Columbia University Irving Medical Center have isolated antibodies from several COVID-19 patients that, to date, are among the most potent in neutralizing ...

GSK and CureVac announce strategic mRNA technology…

GlaxoSmithKline plc (LSE/NYSE: GSK) and CureVac announced the signing of a strategic collaboration agreement for the research, development, manufacturing and commercialis...

Pfizer and BioNTech granted FDA Fast Track designa…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, "BioNTech") announced that two of the companies' four investigational vaccine candidates from their BNT162 mRNA-bas...

Sanofi and Regeneron provide update on Kevzara┬« (s…

Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that the U.S. Phase 3 trial of Kevzara® (sarilumab) 400 mg in COVID-19 patients requiring mechanical v...

Novartis launches first-of-its-kind not-for-profit…

Novartis announced a new initiative to help patients in low-income and lower-middle-income countries (LIC; LMIC) access affordable medicines to treat the major symptoms o...

COVID-19 vaccine AZD1222 showed robust immune resp…

Interim results from the ongoing Phase I/II COV001 trial, led by Oxford University, showed AZD1222 was tolerated and generated robust immune responses against the SARS-Co...

Another mRNA-based vaccine candidate protects anim…

An experimental messenger RNA (mRNA)-based vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) elicits protective immune responses in mice and no...

Pfizer and BioNTech announce an agreement with U.S…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced the execution of an agreement with the U.S. Department of Health and Human Services and the Department of...

Pfizer and BioNTech announce agreement with the Un…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced an agreement with the United Kingdom to supply 30 million doses of their BNT162 mRNA-based vaccine candid...